Cyclin D1 silencing suppresses tumorigenicity, impairs DNA double strand break repair and thus radiosensitizes androgen-independent prostate cancer cells to DNA damage

Oncotarget

Volumn 7, Issue 5, 2016, Pages 5383-5400

  Marampon, F ^a,b   Gravina, G L ^a   Ju, X ^b   Vetuschi, A ^a   Sferra, R ^a   Casimiro, M C ^b   Pompili, S ^a   Festuccia, C ^a   Colapietro, A ^a   Gaudio, E ^c   Di Cesare, E ^a   Tombolini, V ^c   Pestell, R G ^b  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Cyclin D1; DNA double strand break repair; NHEJ; Prostate cancer; Radiotherapy

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ATM PROTEIN; CYCLIN D1; DNA DEPENDENT PROTEIN KINASE; DNA DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT; HISTONE H2AX; RAD51 PROTEIN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; CCND1 PROTEIN, HUMAN; HISTONE; RADIOSENSITIZING AGENT; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RADIOTHERAPY; CARCINOGENICITY; CELL INVASION; CELL MIGRATION; COLONY FORMATION; CONTROLLED STUDY; DNA END JOINING REPAIR; DOUBLE STRANDED DNA BREAK; G1 PHASE CELL CYCLE CHECKPOINT; GENE SILENCING; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROSTATE CANCER; PROSTATE CANCER CELL LINE; RADIOSENSITIVITY; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL ADHESION; CELL MOTION; CELL PROLIFERATION; DNA REPAIR; DRUG SCREENING; ENZYME IMMUNOASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; MALE; METABOLISM; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIATION RESPONSE; RADIATION TOLERANCE; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; CYCLIN D1; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; FLUORESCENT ANTIBODY TECHNIQUE; HISTONES; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MICE; MICE, NUDE; PHOSPHORYLATION; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84958093183     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6579     Document Type: Article

References (50)

1. Hayden AJ, Catton C, Pickles T. Radiation therapy in prostate cancer: a risk-adapted strategy. Curr Oncol. 2010; 17:S18-24.
2. Paller CJ, Antonarakis ES. Management of Biochemically Recurrent Prostate Cancer After Local Therapy: Evolving Standards of Care and New Directions. Clin Adv Hemat Oncol. 2013; 11:14-23.
3. Wu CT, Chen WC, Liao SK, Hsu CL, Lee KD, Chen MF. The radiation response of hormone-resistant prostate cancer induced by long-term hormone therapy. Endoc Relat Canc. 2007; 14:633-43.
4. Karan D, Lin MF, Johansson SL, Batra SK. Current status of the molecular genetics of human prostatic adenocarcinomas. Int J Cancer. 2003; 103:285-93.
5. Rothkamm K, Kruger I, Thompson LH, Lobrich M. Pathways of DNA double-strand break repair during the mammalian cell cycle. Mol Cell Biol. 2003; 23:5706-15.
6. Aylon Y, Liefshitz B, Kupiec M. The CDK regulates repair of double-strand breaks by homologous recombination during the cell cycle. EMBO. 2004; 23:4868-4875.
7. Santivasi WL, Xia F. Ionizing radiation-induced DNA damage, response, and repair. Antioxid Redox Signal. 2014; 21:251-9.
8. Hein AL, Ouellette MM, Yan Y. Radiation-induced signaling pathways that promote cancer cell survival (review). Int J Oncol. 2014; 45:1813-9.
9. Lomax ME1, Folkes LK, O'Neill P. Biological consequences of radiation-induced DNA damage: relevance to radiotherapy. Clin Oncol. 2013; 25:578-85.
10. Srivastava M, Raghavan SC. DNA double-strand break repair inhibitors as cancer therapeutics. Chem Biol. 2015; 22:17-29.
11. Rassool FV, Tomkinson AE. Targeting abnormal DNA double strand break repair in cancer. Cell Mol Life Science. 2010; 67:3699-710.
12. Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 1993; 7:812-21.
13. Massague J. G1 cell-cycle control and cancer. Nature. 2004; 432:298-306.
14. R. G. Pestell. New Roles of Cyclin D1. Am J Pathol. 2013; 183:3-9.
15. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Minireview: Cyclin D1: Normal and Abnormal Functions. Endocrinology. 2004;145:5439-54.
16. Ju X, Casimiro MC, Gormley M, Meng H, Jiao X, Katiyar S, Crosariol M, Chen K, Wang M, Quomg AA, Lisanti MP, Pestell RG. Identification of a Cyclin D1 network in prostate cancer that antagonizes epithelial-mesenchymal restraint. Cancer Res. 2014; 74:508-19.
17. Li Z, Jiao X, Wang C, Shirley LA, Elsaleh H, Dahl O, Wang M, Soutoglou E, Knudsen ES, Pestell RG. Alternative Cyclin D1 splice forms differentially regulate the DNA damage response. Cancer Res. 2010; 70:8802-8811.
18. Wang C, Fan S, Li Z, Fu M, Rao M, Ma Y, Lisanti MP, Albanese C, Katzenellenbogen BS, Kushner PJ, Weber B, Rosen EM, Pestell RG. Cyclin D1 antagonizes BRCA1 repression of estrogen receptor alpha activity. Cancer Res. 2005; 65:6557-6567.
19. Xiong Y, Zhang H, Beach D. D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell. 1992; 71:505-514.
20. Jirawatnotai S, Hu Y, Livingston DM, Sicinski P. Proteomic identification of a direct role for Cyclin D1 in DNA damage repair. Cancer Res. 2012; 72:4289-93.
21. Jirawatnotai S, Hu Y, Michowski W, Elias JE, Becks L, Bienvenu F, Zagozdzon A, Goswami T, Wang YE, Clark AB, Kunkel TA, van Harn T, Xia B, et al. A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers. Nature. 2011; 474:230-4
22. Li Z, Chen K, Jiao X, Wang C, Willmarth NE, Casimiro MC, Li W, Ju X, Kim SH, Lisanti MP, Katzenellenbogen JA, Pestell RG. Cyclin D1 integrates estrogen-mediated DNA damage repair signaling. Cancer Res. 2014; 74:3959-70.
23. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol. 1979; 17:16-23.
24. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ, Lucia MS. Molecular characterization of human prostate carcinoma cell lines. Prostate. 2003; 57:205-225.
25. Bernard D, Pourtier-Manzanedo A, Gil J, Beach DH. Myc confers androgen-independent prostate cancer cell growth. J Clin Invest. 2003; 112:1724-31.
26. Wiznerowicz M, Trono D. Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference. J Virol. 2003; 77:8957-8961.
27. Marampon F, Gravina GL, Zani BM, Popov VM, Fratticci A, Cerasani M, Di Genova D, Mancini M, Ciccarelli C, Ficorella C, Di Cesare E, Festuccia C. Hypoxiasustains glioblastoma radioresistance through ERKs/DNA-PKcs/HIF-1a functional interplay. Int J Oncol. 2014; 44: 2121-31.
28. Marampon F, Gravina GL, Di Rocco A, Bonfili P, Di Staso M, Fardella C, Polidoro L, Ciccarelli C, Festuccia C, Popov VM, Pestell RG, Tombolini V, Zani BM. MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signals. Mol Cancer Ther. 2011; 10:159-68.
29. Gascon-Barrè M, Huet PM, Belgiorno J, PlourdeV, Coulombe PA. Estimation of collagen content of liver specimens. Variation among animals and among hepatic lobes in cirrhotic rats. J Histochem Cytochem. 1989; 37:377-381.
30. Casimiro M, Rodriguez O, Pootrakul L, Aventian M, Lushina N, Cromelin C, Ferzli G, Jounson K, Fricke S, Diba F, Kallakury B, Ohanyerenwa C, Chen M, et al. ErbB-2 induces the Cyclin D1 gene in prostate epithelial cells in vitro and in vivo. Cancer Res. 2007; 67:4364-72.
31. Chen Y, Martinez LA, La Cava M, Coghlan L, Conti CJ. Increased cell growth and tumorigenicity in human prostate LNCaP cells by overexpression to Cyclin D1. Oncogene. 1998; 16:1913-20.
32. Pickup MW, Mouw JK, Weaver VM. The extracellular matrix modulates the hallmarks of cancer. EMBO Rep. 2014; 15:1243-53.
33. Li Z, Wang C, Prendergast GC, Pestell RG. Cyclin D1 functions in cell migration. Cell Cycle. 2006; 5:2440-2.
34. Neumeister P, Pixley FJ, Xiong Y, Xie H, Wu K, Ashton A, Cammer M, Chan A, Symons M, Stanley ER, Pestell RG. Cyclin D1 governs adhesion and motility of macrophages. Mol Cell Biol. 2003; 14:2005-15.
35. Li Z, Wang C, Jiao X, Lu Y, Fu M, Quong AA, Dye C, Yang J, Dai M, Ju X, Zhang X, Li A, Burbelo P. Cyclin D1 regulates cellular migration through the inhibition of thrombospondin 1 and ROCK signaling. Mol Cell Biol. 2006; 26:4240-56.
36. Li Z, Jiao X, Wang C, Ju X, Lu Y, Yuan L, Lisanti MP, Katiyar S, Pestell RG. Cyclin D1 induction of cellular migration requires p27(KIP1). Cancer Res. 2006; 66: 9986-94.
37. Wang J, Wang Q, Cui Y, Liu ZY, Zhao W, Wang CL, Dong Y, Hou L, Hu G, Luo C, Chen J, Lu Y. Knockdown of Cyclin D1 inhibits proliferation, induces apoptosis, and attenuates the invasive capacity of human glioblastoma cells. J Neurooncol. 2012; 106:473-84.
38. Arato-Ohshima T, Sawa H. Over-expression of Cyclin D1 induces glioma invasion by increasing matrix metalloproteinase activity and cell motility. Int J Cancer. 1999; 83:387-92.
39. Zhong Z, Yeow WS, Zou C, Wassell R, Wang C, Pestell RG, Quong JN, Quong AA. Cyclin D1/cyclin-dependent kinase 4 interacts with Filamin A and affects the migration and invasion potential of breast cancer cells. Cancer Res. 2010; 70:2005-14.
40. Meng H, Tian L, Zhou J, Jiao X, Li WW, Plomann M, Xu Z, Lisanti MP, Wang C, Pestell RG. PACSIN 2 represses cellular migration through direct association with Cyclin D1 but not its alternate splice form Cyclin D1b. Cell Cycle. 2011; 10:73-81.
41. Yu Z, Willmarth NE, Zhou J, Katiyar S, Wang M, Liu Y, McCue PA, Quong AA, Lisanti MP, Pestell RG. microRNA 17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling. Proc Natl Acad Sci U S A. 2010; 107:8231-6.
42. Lin HM, Lee YJ, Li G, Pestell RG, Kim HR. Bcl-2 induces cyclin D1 promoter activity in human breast epithelial cells independent of cell anchorage. Cell Death Differ. 2001; 8:44-50.
43. Casimiro MC, Wang C, Li Z, Di Sante G, Willmart NE, Addya S, Chen L, Liu Y, Lisanti MP, Pestell RG. Cyclin D1 determines estrogen signaling in the mammary gland in vivo. Mol Endocrinol. 2013; 27:1415-28.
44. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. "Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma". Am J Pathol. 1993; 143:401-409.
45. Yasui M, Yamamoto H, Ngan CY, Damdinsuren B, Sugita Y, Fukunaga H, Gu J, Maeda M, Takemasa I, Ikeda M, Fujio Y, Sekimoto M, Matsuura N, et al. Antisense to cyclin D1 inhibits vascular endothelial growth factor-stimulated growth of vascular endothelial cells: implication of tumor vascularization. Clin Cancer Res. 2006; 12:4720-9.
46. Richard G. Pestell, Zhiping Li. Antisense to Cyclin D1 Inhibits VEGF-Stimulated Growth of Vascular Endothelial Cells: Implication of Tumor Vascularization. Clin Cancer Res. 2006; 12:4459-4462.
47. Ross GM. Induction of cell death by radiotherapy. Endocr Relat Cancer. 1999; 6:41-4.
48. Kuo LJ, Yang LX. Gamma-H2AX a novel biomarker for DNA double-strand breaks. In vivo. 2008; 22:305-9.
49. Rycaj K, Tang DG. Cancer stem cells and radioresistance. Int J Radiat Biol. 2014; 90:615-21.
50. Alberti C. Prostate cancer: radioresistance molecular target-related markers and foreseeable modalities of radiosensitization. Eur Rev Med Pharmacol Sci. 2014; 18:2275-82.